ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.134,94
-0,61%
S&P 500
6.040,53
-0,50%
US Dollar vs BRL
5,842
0,00%
Bitcoin
102.069,33
-0,34%
Brent Oil
76,385
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) Notícias

RIGL

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RIGL
DataHoraFonteTítuloCódigoCompanhia
31/01/202520:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
24/01/202518:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RIGLRigel Pharmaceuticals Inc
22/01/202510:05PR Newswire (US)Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell DiseaseNASDAQ:RIGLRigel Pharmaceuticals Inc
13/01/202510:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RIGLRigel Pharmaceuticals Inc
13/01/202510:05PR Newswire (US)Rigel Provides Business Update and 2025 OutlookNASDAQ:RIGLRigel Pharmaceuticals Inc
09/01/202510:05PR Newswire (US)Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDSNASDAQ:RIGLRigel Pharmaceuticals Inc
08/01/202510:05PR Newswire (US)Rigel to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
03/01/202510:05PR Newswire (US)Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
09/12/202414:02PR Newswire (US)Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionNASDAQ:RIGLRigel Pharmaceuticals Inc
02/12/202410:05PR Newswire (US)Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDSNASDAQ:RIGLRigel Pharmaceuticals Inc
14/11/202419:18Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RIGLRigel Pharmaceuticals Inc
12/11/202410:05PR Newswire (US)Rigel to Present at the Jefferies London Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
07/11/202418:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RIGLRigel Pharmaceuticals Inc
07/11/202418:01PR Newswire (US)Rigel Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
05/11/202411:05PR Newswire (US)Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:RIGLRigel Pharmaceuticals Inc
31/10/202409:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
24/10/202417:35PR Newswire (US)Rigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)NASDAQ:RIGLRigel Pharmaceuticals Inc
16/10/202411:00GlobeNewswire Inc.Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®NASDAQ:RIGLRigel Pharmaceuticals Inc
04/10/202409:05PR Newswire (US)Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:RIGLRigel Pharmaceuticals Inc
12/09/202409:05PR Newswire (US)Rigel to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:RIGLRigel Pharmaceuticals Inc
05/09/202408:30PR Newswire (US)Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AMLNASDAQ:RIGLRigel Pharmaceuticals Inc
03/09/202409:00PR Newswire (US)Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and TaiwanNASDAQ:RIGLRigel Pharmaceuticals Inc
29/08/202409:05PR Newswire (US)Rigel to Participate in Upcoming September Investor ConferencesNASDAQ:RIGLRigel Pharmaceuticals Inc
12/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RIGLRigel Pharmaceuticals Inc
06/08/202418:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RIGLRigel Pharmaceuticals Inc
06/08/202417:01PR Newswire (US)Rigel Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
02/08/202417:53Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RIGLRigel Pharmaceuticals Inc
30/07/202409:05PR Newswire (US)Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business UpdateNASDAQ:RIGLRigel Pharmaceuticals Inc
25/06/202409:00PR Newswire (US)Rigel Announces Reverse Stock SplitNASDAQ:RIGLRigel Pharmaceuticals Inc
24/06/202417:05PR Newswire (US)Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug ApplicationNASDAQ:RIGLRigel Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RIGL

Seu Histórico Recente

BIT
P1MA63
BNP Paribas Issuance
ASX
WINN
Widgie Nickel
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios